BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 26, 2026
Home » Topics » Briefs

Briefs
Briefs RSS Feed RSS

Regulatory actions for April 5, 2023

April 5, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acasti, Aim, Amarin, Astellas, Caribou, Gennova, Hutchmed, Pfizer, Phathom, Scisparc, Seagen, Shionogi.
Read More

Other news to note for April 5, 2023

April 5, 2023
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelrx, Aeterna, Alora, Anagram, Biomed X, Biotheryx, Cyclerion, Dr. Reddy’s, Eagle, Ginkgo, Incyte, Liminal, Merck KGaA, Scilex, Sorrento, Stridebio.
Read More

In the clinic for April 5, 2023

April 5, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzamend, Alterity, Arrowhead, Axial, Bioarctic, EIP, Eisai, Innocare, Iomx, Lundbeck, Lynk, Mythic, Otsuka, Precision, Skye, Sobi, Takeda.
Read More

Financings for April 5, 2023

April 5, 2023
Biopharmas raising money in public or private financings, including:  Addex, Celularity, Cellectis, Protagonist, Transcode.
Read More

Appointments and advancements for April 5, 2023

April 5, 2023
New hires and promotions in the biopharma industry, including: Biorchestra, Clearside, Clexbio, Generation, Rocket, Sisaf, Sparingvision, Surrozen, Walden.
Read More

Appointments and advancements for April 4, 2023

April 4, 2023
New hires and promotions in the biopharma industry in Asia-Pacific, including: Bioduro-Sundia, Hanall.
Read More

Regulatory actions for April 4-10, 2023

April 4, 2023
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Aim Immunotech, Astellas, Brim, Edesa, Everest Medicines, Gennova, Hutchmed, Inflarx, Seagen, Shionogi.
Read More

Regulatory actions for March 28-April 3, 2023

April 4, 2023
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Athos, Huidagene, Hutchmed, Immvira, Incyte, Samsung Bioepis, Transcenta.
Read More

In the clinic for March 28-April 3, 2023

April 4, 2023
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Actinogen Medical, Bioxytran, Dxvx C., Eisai, Immutep, Invivyd, Kintor, Olix, Takeda, Vacmedix UK, Yishengbio.
Read More

Other news to note for April 4, 2023

April 4, 2023
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Ablaze, Alexion, Aquestive, Astellas, Astrazeneca, Atnahs, Beigene, BJ, Enlivex, Immunoprecise Antibodies, JCR, Keymed, Kym, Lepu Medical Technology, Mallinckrodt, Merck, Micurx, Mimetas, Mitsubishi Tanabe, Noxopharm, Oncovent, Orient Europharma, Rayzebio, Regimmune, San Fu, Scineuro, Secarna, Shenzhen Hepalink, Silence, Xyphos.
Read More
Previous 1 2 … 809 810 811 812 813 814 815 816 817 … 1786 1787 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Illustration of metastatic cancer

    At AACR: Epigenetic fingerprints in metastases track tumor origin

    BioWorld
    When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing